Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 36

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 36
---
 to antimicrobial therapy that offers promising opportunities to overcome the emergence and increasing prevalence of antibiotic -resistantbacteria. SACT -1is the first repurposed drug candidate to be developed under the Smart -ACT ®drug discovery platform. SCAT -1is one of the Company’s proprietary technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare form of cancer, and classified as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine, chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below. In March 2023, Aptorum announced that it completed the Pre -INDdiscussions with the US FDA on ALS -4. With the positive feedback on the overall development strategy from the US FDA, it is proceeding towards the IND submission of ALS -4. In March 2023, Aptorum also announced the completion of the End of Phase 1 (EOP1) meeting of SACT -1with the US FDA. The FDA generally agreed with the chemistry -manufacturing-control(CMC) strategy and Aptorum’s proposed clinical development plan for SACT -1Phase 1/2 trials. The timing and scope of advancing both ALS -4Phase 2 clinical trials and SACT -1Phase 1/2 trials will be contingent upon securing appropriate collaborative partnerships and adequate funding resources. The Company is actively seeking strategic collaborators who can provide both financial support and clinical expertise to advance these therapeutic programs. 1 During the second quarter of 2023, Aptorum decided to streamline its operations by terminating clinic services and suspending non -leadR&D projects. This was done to optimize the allocation of Aptorum’s resources and focusing efforts on advancing Aptorum’s lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with its commitment to enhance shareholder value and effectively drive its core objectives forward in the competitive landscape. DiamiR DiamiR Biosciences Corp. (“DiamiR”) is a molecular diagnostic company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at DiamiR is based on quantitative analysis of circulating organ -enrichedmicroRNAs in plasma. Long term objectives of DiamiR include the development and commercialization of Lab -Developedtests (LDTs) from its CLIA certified